Don’t give in to big pharma on drug pricing | Letters

The article discusses the debate around drug pricing in the UK. The author argues that the UK's system for evaluating the cost-effectiveness of new drugs is respected globally and has led to widespread price reductions, allowing the National Health Service (NHS) to benefit. The article refutes the claim by the chief executive of Eli Lilly that the UK is the "worst country in Europe" for drug prices, stating that the recent pausing or cancelling of pharmaceutical industry investments in the UK is due to the companies' desperation to appease former US President Donald Trump, not the UK's drug pricing policies. The author suggests that the NHS should celebrate its drug pricing system, which upholds the principle that funding a new product should not damage the NHS as a whole.